Laura Mitic, PhD

Title(s)Specialist, Neurology
SchoolSchool of Medicine
Address550 16th Street, #5650
San Francisco CA 94158
Phone415-514-8043
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences


    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco, San FranciscoPostdoctoral Studies2008Genetics of Aging
    Yale University, New HavenPostdoctoral Studies2002Structural Biology
    Yale University, New HavenPhD2000Cell Biology
    Northwestern University, EvanstonBA1995Molecular Cell Biology

    Collapse Overview 
    Collapse Overview
    As the Chief Scientific Officer for the Bluefield Project to Cure Frontotemporal Dementia, I work to enable and accelerate basic, clinical and translational research in frontotemporal dementia (FTD) caused by mutations in the lysosomal protein progranulin (GRN). With our aggressive timeline to find a cure or therapy for GRN-FTD, I foster highly focused, rapid and collaborative discovery research and engage with industry partners to advance drug development for this devastating disease.

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration. Alzheimer's & Dementia. 2022 Dec 20; 18(S5). Acuna-Narvaez AR, Heuer HH, Forsberg FL, Alward AA, Graham GD, Fishman FA, Nelson NK, Kolander KT, Fillit FH, Galpern GW, Hung HS, Mason MC, Mignon ML, Ni NY, Simen SA, Tesseur TI, Tsai TR, Yeh YF, Mester MC, Ljubenkov LP, Rosen RH, Boeve BB, Boxer BA, Pearlman PR, Mitic ML, Investigators IN. .
      View in: Publisher Site   Mentions:
    2. The role of neurofilament light in genetic frontotemporal lobar degeneration. Brain Commun. 2023; 5(1):fcac310. Zetterberg H, Teunissen C, van Swieten J, Kuhle J, Boxer A, Rohrer JD, Mitic L, Nicholson AM, Pearlman R, McCaughey SM, Tatton N. PMID: 36694576; PMCID: PMC9866262.
      View in: PubMed   Mentions: 3  
    3. Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology. 2021 05 04; 96(18):e2296-e2312. Rojas JC, Wang P, Staffaroni AM, Heller C, Cobigo Y, Wolf A, Goh SM, Ljubenkov PA, Heuer HW, Fong JC, Taylor JB, Veras E, Song L, Jeromin A, Hanlon D, Yu L, Khinikar A, Sivasankaran R, Kieloch A, Valentin MA, Karydas AM, Mitic LL, Pearlman R, Kornak J, Kramer JH, Miller BL, Kantarci K, Knopman DS, Graff-Radford N, Petrucelli L, Rademakers R, Irwin DJ, Grossman M, Ramos EM, Coppola G, Mendez MF, Bordelon Y, Dickerson BC, Ghoshal N, Huey ED, Mackenzie IR, Appleby BS, Domoto-Reilly K, Hsiung GR, Toga AW, Weintraub S, Kaufer DI, Kerwin D, Litvan I, Onyike CU, Pantelyat A, Roberson ED, Tartaglia MC, Foroud T, Chen W, Czerkowicz J, Graham DL, van Swieten JC, Borroni B, Sanchez-Valle R, Moreno F, Laforce R, Graff C, Synofzik M, Galimberti D, Rowe JB, Masellis M, Finger E, Vandenberghe R, de Mendonça A, Tagliavini F, Santana I, Ducharme S, Butler CR, Gerhard A, Levin J, Danek A, Otto M, Sorbi S, Cash DM, Convery RS, Bocchetta M, Foiani M, Greaves CV, Peakman G, Russell L, Swift I, Todd E, Rohrer JD, Boeve BF, Rosen HJ, Boxer AL, ALLFTD and GENFI consortia. PMID: 33827960; PMCID: PMC8166434.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    4. Peripheral Innate Immune Activation Correlates With Disease Severity in GRN Haploinsufficiency. Front Neurol. 2019; 10:1004. Ljubenkov PA, Miller Z, Mumford P, Zhang J, Allen IE, Mitic L, Staffaroni A, Heuer H, Rojas JC, Cobigo Y, Karydas A, Pearlman R, Miller B, Kramer JH, McGrath MS, Rosen HJ, Boxer AL. PMID: 31620075; PMCID: PMC6759464.
      View in: PubMed   Mentions: 5  
    5. Peripheral Innate Immune Activation Correlates with Disease Severity in GRN Mutation Carriers (P4.178). Neurology. 2018 Apr 10; 90(15_supplement). Ljubenkov LP, Mumford MP, McGrath MM, Allen AI, Miller MZ, Mitic ML, Karydas KA, Heuer HH, Rojas-Martinez RJ, Wang WP, Zhang ZJ, Staffaroni SA, Cobigo CY, Pearlman PR, Miller MB, Rosen RH, Boxer BA. .
      View in: Publisher Site   Mentions:
    6. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimers Dement (N Y). 2017 Nov; 3(4):507-512. Sha SJ, Miller ZA, Min SW, Zhou Y, Brown J, Mitic LL, Karydas A, Koestler M, Tsai R, Corbetta-Rastelli C, Lin S, Hare E, Fields S, Fleischmann KE, Powers R, Fitch R, Martens LH, Shamloo M, Fagan AM, Farese RV, Pearlman R, Seeley W, Miller BL, Gan L, Boxer AL. PMID: 29124108; PMCID: PMC5671622.
      View in: PubMed   Mentions: 16  
    7. Prosaposin is a regulator of progranulin levels and oligomerization. Nat Commun. 2016 06 30; 7:11992. Nicholson AM, Finch NA, Almeida M, Perkerson RB, van Blitterswijk M, Wojtas A, Cenik B, Rotondo S, Inskeep V, Almasy L, Dyer T, Peralta J, Jun G, Wood AR, Frayling TM, Fuchsberger C, Fowler S, Teslovich TM, Manning AK, Kumar S, Curran J, Lehman D, Abecasis G, Duggirala R, Pottier C, Zahir HA, Crook JE, Karydas A, Mitic L, Sun Y, Dickson DW, Bu G, Herz J, Yu G, Miller BL, Ferguson S, Petersen RC, Graff-Radford N, Blangero J, Rademakers R. PMID: 27356620; PMCID: PMC4931318.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    8. MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes. Alzheimers Dement (Amst). 2016; 3:91-7. Bettcher BM, Fitch R, Wynn MJ, Lalli MA, Elofson J, Jastrzab L, Mitic L, Miller ZA, Rabinovici GD, Miller BL, Kao AW, Kosik KS, Kramer JH. PMID: 27453930; PMCID: PMC4941041.
      View in: PubMed   Mentions: 37  
    9. Progranulin protein plasma and CSF levels in a large well-characterized dementia and healthy aging cohort. (S33.004). Neurology. 2015 Apr 6; 84(14_supplement). Miller MZ, Mitic ML, Tran TJ, Lobach LI, Karydas KA, Serrero SG, Pearlman PR, Rosen RH, Miller MB, Boxer BA. .
      View in: Publisher Site   Mentions:
    10. Progranulin: at the interface of neurodegenerative and metabolic diseases. Trends Endocrinol Metab. 2013 Dec; 24(12):597-606. Nguyen AD, Nguyen TA, Martens LH, Mitic LL, Farese RV. PMID: 24035620; PMCID: PMC3842380.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimals
    11. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013 Mar; 9(2):189-98. Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. PMID: 23062850; PMCID: PMC3562382.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    12. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013 Mar; 9(2):176-88. Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J. PMID: 23043900; PMCID: PMC3542408.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimals
    13. SUMOylation of claudin-2. Ann N Y Acad Sci. 2012 Jul; 1258:60-4. Van Itallie CM, Mitic LL, Anderson JM. PMID: 22731716.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    14. Claudin-2 forms homodimers and is a component of a high molecular weight protein complex. J Biol Chem. 2011 Feb 04; 286(5):3442-50. Van Itallie CM, Mitic LL, Anderson JM. PMID: 21098027; PMCID: PMC3030350.
      View in: PubMed   Mentions: 45     Fields:    Translation:AnimalsCells
    15. A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet. 2008 Feb; 4(2):e24. Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon C. PMID: 18282106; PMCID: PMC2242811.
      View in: PubMed   Mentions: 370     Fields:    Translation:Animals
    16. A Role for Autophagy Genes in the Extension of Lifespan by Dietary Restriction in C. elegans. PLoS Genetics. 2005 Jan 1; preprint(2008):e24. Hansen HM, Chandra CA, Mitic ML, Onken OB, Driscoll DM, Kenyon KC. .
      View in: Publisher Site   Mentions:
    17. Expression, solubilization, and biochemical characterization of the tight junction transmembrane protein claudin-4. Protein Sci. 2003 Feb; 12(2):218-27. Mitic LL, Unger VM, Anderson JM. PMID: 12538885; PMCID: PMC2312412.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    18. Comparative biochemical and immunocytochemical studies reveal differences in the effects of Clostridium perfringens enterotoxin on polarized CaCo-2 cells versus Vero cells. J Biol Chem. 2001 Sep 07; 276(36):33402-12. Singh U, Mitic LL, Wieckowski EU, Anderson JM, McClane BA. PMID: 11445574.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    19. Occludin and Claudins. Tight Junctions. 2001 Jun 26. Mitic ML, Van Itallie VC. .
      View in: Publisher Site   Mentions:
    20. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology. 2001 Feb; 120(2):411-22. Rahner C, Mitic LL, Anderson JM. PMID: 11159882.
      View in: PubMed   Mentions: 183     Fields:    Translation:AnimalsCells
    21. Occludin localization at the tight junction requires the second extracellular loop. J Membr Biol. 2000 Dec 01; 178(3):235-47. Medina R, Rahner C, Mitic LL, Anderson JM, Van Itallie CM. PMID: 11140279.
      View in: PubMed   Mentions: 28     Fields:    Translation:AnimalsCells
    22. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol. 2000 Aug; 279(2):G250-4. Mitic LL, Van Itallie CM, Anderson JM. PMID: 10915631.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansAnimalsCells
    23. CaCo-2 cells treated with Clostridium perfringens enterotoxin form multiple large complex species, one of which contains the tight junction protein occludin. J Biol Chem. 2000 Jun 16; 275(24):18407-17. Singh U, Van Itallie CM, Mitic LL, Anderson JM, McClane BA. PMID: 10749869.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    24. Connexin-occludin chimeras containing the ZO-binding domain of occludin localize at MDCK tight junctions and NRK cell contacts. J Cell Biol. 1999 Aug 09; 146(3):683-93. Mitic LL, Schneeberger EE, Fanning AS, Anderson JM. PMID: 10444075; PMCID: PMC2150551.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    25. Transmembrane proteins in the tight junction barrier. J Am Soc Nephrol. 1999 Jun; 10(6):1337-45. Fanning AS, Mitic LL, Anderson JM. PMID: 10361874.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansAnimalsCells
    26. Molecular architecture of tight junctions. Annu Rev Physiol. 1998; 60:121-42. Mitic LL, Anderson JM. PMID: 9558457.
      View in: PubMed   Mentions: 194     Fields:    Translation:HumansAnimalsCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Laura's Networks
    Concepts (137)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (26)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.